Description
Product details
How are conjugated primary antibodies validated? This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling. For suitable applications and species reactivity, please refer to the unconjugated version of this clone.
What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on recombinant antibodies.
Patented technology Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
DLL3 functions mainly in the modulation of the Notch signaling pathway. It does not activate this pathway but acts as an inhibitor blocking Notch ligand activation on adjacent cells. DLL3's role involves binding directly to Notch receptors altering cellular differentiation and growth processes. Despite being related to the Delta/Serrate/LAG-2 family DLL3 exhibits unique characteristics in its interactions forming part of a regulatory complex different from its family members.
Pathways
DLL3 engages importantly in the Notch signaling pathway affecting important cellular communications that regulate development and differentiation. Its interaction with proteins of the Notch family specifically the Notch receptors highlights its inhibitory role. Additionally DLL3 intersects with the Wnt signaling pathway though indirect influencing its output by modulating availability of pathway regulators.